Detalles de la búsqueda
1.
Implementing well-being in the management of psoriasis: An expert recommendation.
J Eur Acad Dermatol Venereol
; 38(2): 302-310, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37822008
2.
Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks.
Acta Derm Venereol
; 103: adv17752, 2023 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37877618
3.
Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice.
J Eur Acad Dermatol Venereol
; 37(10): 2004-2015, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37246505
4.
Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years.
J Eur Acad Dermatol Venereol
; 37(4): e501-e504, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36433779
5.
Differential expression of postsynaptic NMDA and AMPA receptor subunits in the hippocampus and prefrontal cortex of the flinders sensitive line rat model of depression.
Synapse
; 70(11): 471-4, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27262028
6.
Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest.
J Dermatolog Treat
; 34(1): 2220447, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37341303
Resultados
1 -
6
de 6
1
Próxima >
>>